Article
Cell Biology
Zhe Liu, Liang Ma, Yiming Sun, Wenying Yu, Xue Wang
Summary: The study demonstrated that the STAT3/ZEB1 axis is critical in gefitinib resistance in lung cancer, and a new potential therapeutic strategy targeting STAT3 has been identified with the inhibitor LL1. LL1 was shown to sensitize resistant cells to gefitinib by depleting STAT3 activity and blocking its signaling pathways, with little observed toxicity in animal models, indicating it could be a chemotherapeutic adjuvant for gefitinib resistance in NSCLC.
CELL DEATH & DISEASE
(2021)
Article
Chemistry, Multidisciplinary
Jian Zhang, Bin Fu, Meng Li, Shuangli Mi
Summary: This study uses quantitative proteomics to identify diagnostic markers and a prognostic signature based on differential protein secretion by normal fibroblasts and exosome-activated fibroblasts affected by lung cancer cell-derived exosomes. These findings have the potential to distinguish tumor tissues from normal tissue and identify patients who may benefit from adjuvant therapy after surgical resection. Additionally, the secretome offers novel targets for clinical treatment.
Article
Medicine, General & Internal
Jingsheng Cai, Fan Yang, Xun Wang
Summary: This study aims to investigate occult non-small cell lung cancer (NSCLC), an underappreciated tumor, and found that it is an aggressive tumor with poor prognosis. Surgery is the preferred treatment. More attention should be paid to this overlooked disease due to no evidence of tumor imaging.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Shawn J. Rice, Chandra P. Belani
Summary: Blood-based biomarkers, including systemic inflammation indicators and circulating factors, are associated with poor prognosis in lung cancer patients. Elevated levels of inflammation markers were found in non-small cell lung cancer (NSCLC) patients compared to small cell lung cancer (SCLC) and disease-free (DF) patients. Specific markers were identified as predictors of progression and overall survival in NSCLC patients, highlighting the potential for personalized treatment strategies.
Article
Biotechnology & Applied Microbiology
Fan Yang, Chunlan Ma, Jing Qiu, Xiaoli Feng, Kai Yang
Summary: This study identified 114 circRNAs that were differentially expressed in NSCLC tissue compared to paracancerous tissue levels, with 77 downregulated and 37 upregulated. CircRNA_001846 may serve as a promising diagnostic biomarker for NSCLC, associated with tumor differentiation, lymph node metastasis, and node metastasis stage.
Article
Oncology
Lin Zhou, Xiaomu Wang, Jingya Lu, Xiangning Fu, Yangkai Li
Summary: In this study, we found that UTX expression is significantly upregulated in cancer tissues of NSCLC patients, positively correlated with EGFR phosphorylation levels. UTX promotes proliferation and migration in NSCLC cell lines, and is closely associated with the EGFR signaling pathway.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Jacob G. Ellen, Etai Jacob, Nikos Nikolaou, Natasha Markuzon
Summary: This study presents a multimodal integration approach utilizing multiple omics data to predict NSCLC patient survival and identify patient subtypes. The results demonstrate that combining multiple modalities in survival prediction models outperforms using a single modality, with the combination of lncRNA and clinical data achieving the highest performance.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Eabha O'Sullivan, Anna Keogh, Brian Henderson, Stephen P. Finn, Steven G. Gray, Kathy Gately
Summary: KRAS plays a crucial role in regulating cell growth and survival, and its activation is commonly observed in various types of tumors. Recent discoveries have identified a specific pocket in the structure of KRAS, leading to the development of inhibitors that target the G12C mutation. These inhibitors, such as sotorasib and adagrasib, have been approved for the treatment of non-small-cell lung cancer, but their efficacy may be limited by resistance mechanisms in cancer cells.
Article
Plant Sciences
Yili Shen, Haijian Cai, Shenjie Ma, Wenjing Zhu, Haiyang Zhao, Jifa Li, Hua Ye, Lehe Yang, Chengguang Zhao, Xiaoying Huang, Zhongxiao Xiao
Summary: Telocinobufagin can inhibit proliferation and metastasis, and induce apoptosis in non-small-cell lung cancer cells. Its mechanism of action involves inhibition of STAT3 phosphorylation and downstream targets, as well as interference with IL-6-induced STAT3 nuclear translocation.
JOURNAL OF NATURAL PRODUCTS
(2022)
Review
Oncology
Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar, Chukwuemeka V. Ikpeazu
Summary: Recent FDA approvals for tumor-agnostic drugs have shifted cancer treatment from organ/histology-specific strategies to biomarker-guided approaches. RET gene fusions, known oncogenic drivers in various tumors, can be effectively targeted by inhibitors like selpercatinib and pralsetinib, showing significant clinical benefits in NSCLC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka Ikpeazu
Summary: The MET exon 14 skipping mutation is present in a small percentage of lung cancer patients, but targeted inhibitors like capmatinib and tepotinib show promising clinical activity with tolerable toxicity profiles. Ongoing research aims to overcome acquired resistance and enhance the effectiveness of these agents.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Olga V. Kovaleva, Madina A. Rashidova, Daria V. Samoilova, Polina A. Podlesnaya, Rasul M. Tabiev, Valeria V. Mochalnikova, Alexei Gratchev
Summary: In this study, immune cell markers in NSCLC specimens were evaluated, with CD163 and CD206 showing prognostic value, especially in patients with squamous cell lung carcinoma and adenocarcinoma. Additionally, iNOS and CHID1 were found to be expressed in tumor cells and associated with prognosis, indicating potential as therapeutic targets in NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Xi Chen, Jianzhang Wu, Jiabing Wang
Summary: Pyroptosis, a distinct form of cell death, has shown potential as a therapeutic strategy and prognosis for NSCLC. However, activating pyroptosis in NSCLC treatment still poses challenges.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Qing Ye, Rehab Mohamed, Duaa Dakhlallah, Marieta Gencheva, Gangqing Hu, Martin C. Pearce, Siva Kumar Kolluri, Clay B. Marsh, Timothy D. Eubank, Alexey V. Ivanov, Nancy Lan Guo
Summary: This study demonstrated that high expression of ZNF71 KRAB is associated with poor survival outcomes in NSCLC patients, as well as with epithelial-to-mesenchymal transition and chemotherapy resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, Research & Experimental
Sung Baek Jeong, Raju Das, Dong-Hyun Kim, Sion Lee, Hye In Oh, Sungwoo Jo, Yechan Lee, Jeongdong Kim, SeonJu Park, Dong Kyu Choi, Uk Yeol Moon, Oh-bin Kwon, Wan Namkung, Sungwoo Lee, Byoung Chul Cho, Joohan Woo, Yohan Seo
Summary: In this study, verteporfin was found to reduce ANO1 protein levels and inhibit the growth of non-small cell lung cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2022)